E Fund Management Co. Ltd. Grows Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

E Fund Management Co. Ltd. boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,495 shares of the company’s stock after acquiring an additional 808 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Krystal Biotech were worth $558,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its position in Krystal Biotech by 111.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after purchasing an additional 379 shares during the period. Fox Run Management L.L.C. purchased a new stake in Krystal Biotech during the third quarter worth about $219,000. Prime Capital Investment Advisors LLC purchased a new stake in Krystal Biotech during the fourth quarter worth about $310,000. Graham Capital Management L.P. acquired a new stake in shares of Krystal Biotech during the third quarter worth about $330,000. Finally, Confluence Wealth Services Inc. boosted its stake in shares of Krystal Biotech by 20.7% in the third quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock valued at $339,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $4.08 during trading hours on Wednesday, hitting $157.68. The company had a trading volume of 244,959 shares, compared to its average volume of 363,836. The company’s 50-day moving average is $168.76 and its two-hundred day moving average is $134.27. Krystal Biotech, Inc. has a twelve month low of $86.03 and a twelve month high of $189.97. The company has a market cap of $4.50 billion, a P/E ratio of 1,971.25 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. The company’s quarterly revenue was up 452400.0% on a year-over-year basis. During the same period last year, the firm posted ($1.76) EPS. Sell-side analysts expect that Krystal Biotech, Inc. will post 1.82 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on KRYS. Stifel Nicolaus reiterated a “buy” rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. William Blair reissued an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Citigroup upped their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Guggenheim boosted their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a research report on Monday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $171.00.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Insiders sold a total of 38,087 shares of company stock worth $6,210,591 in the last 90 days. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).